Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neurofibromatosis 1 7Neurofibroma, Plexiform 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 2Recurrence 1Pain 1Neoplasms 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Melanoma 1Gallbladder Neoplasms 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1

Interventions

Gemcitabine 6Cisplatin 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Capecitabine 4Biopsy 3pembrolizumab 2durvalumab 2Trastuzumab 2Platinum 2Oxaliplatin 2Leucovorin 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2varlilumab 1tucatinib 1toripalimab 1peposertib 1guadecitabine 1dehydroftorafur 1cobimetinib 1binimetinib 1avelumab 1atezolizumab 1Tegafur 1Taxes 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gallbladder Neoplasms × AZD 6244 × Clear all
NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
57 enrolled
Gastrointestinal

Gallbladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡